BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/22/2019 2:04:16 AM | Browse: 681 | Download: 805
 |
Received |
|
2019-03-29 01:51 |
|
Peer-Review Started |
|
2019-04-03 08:30 |
|
To Make the First Decision |
|
2019-08-06 06:58 |
|
Return for Revision |
|
2019-08-20 02:14 |
|
Revised |
|
2019-08-22 15:44 |
|
Second Decision |
|
2019-09-29 07:06 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2019-10-07 19:09 |
|
Articles in Press |
|
2019-10-07 19:09 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2019-10-31 05:26 |
|
Publish the Manuscript Online |
|
2019-11-22 02:04 |
| ISSN |
1949-8462 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Cardiac & Cardiovascular Systems |
| Manuscript Type |
Editorial |
| Article Title |
Novel lipid-modifying therapies addressing unmet needs in cardiovascular disease
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Constantine E Kosmas, Andreas Sourlas, Delia Silverio, Peter D Montan and Eliscer Guzman |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Constantine E Kosmas, FACC, FACP, MD, PhD, Attending Doctor, Department of Medicine, Division of Cardiology, Montefiore Medical Center, 111 E 210th St, Bronx, NY 10467, United States. cekosmas1@gmail.com |
| Key Words |
Lipid-modifying therapies; Cardiovascular disease; Dyslipidemia; ; ; |
| Core Tip |
Despite significant progress in the treatment of dyslipidemia, there is still considerable residual risk of recurring cardiovascular events. Ongoing research has led to the discovery of several different molecules involved in lipid homeostasis, which can serve as possible targets for new lipid-modifying therapies. Novel medications that have provided promising results in early human trials include inclisiran, bempedoic acid, seladelpar, CSL-112, apabetalone, volanesorsen, APO(a)-RX, and APO(a)-LRX. Furthermore, several other lipid-lowering agents are being evaluated in ongoing trials. Thus, there is optimism that use of these lipid-lowering medications may in the future lead to a reduction of the residual cardiovascular risk. |
| Publish Date |
2019-11-22 02:04 |
| Citation |
Kosmas CE, Sourlas A, Silverio D, Montan PD, Guzman E. Novel lipid-modifying therapies addressing unmet needs in cardiovascular disease. World J Cardiol 2019; 11(11): 256-265 |
| URL |
https://www.wjgnet.com/1949-8462/full/v11/i11/256.htm |
| DOI |
https://dx.doi.org/10.4330/wjc.v11.i11.256 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
